Document is current
Any future updates will be listed below
-
Authors
Ligero, Marta
Hernando, Jorge
Delgado, Eric
Garcia-Ruiz, Alonso
Merino-Casabiel, Xavier
Ibrahim, Toni
Fazio, Nicola
Lopez, Carlos
Teulé, Alexandre
Valle, Juan W.
Tafuto, Salvatore
Custodio, Ana
Reed, Nicholas
Raderer, Markus
Grande, Enrique
Garcia-Carbonero, Rocio
Jimenez-Fonseca, Paula
Garcia-Alvarez, Alejandro
Escobar, Manuel
Casanovas, Oriol
Capdevila, Jaume
Perez-Lopez, Raquel https://orcid.org/0000-0002-9176-0130
-
Funding
Funding for this research was provided by:
PERIS-Predoctoral fellowship (SLT017/20/000080)
CRIS Foundation Talent Award (TALENT19-05)
Instituto de Salud Carlos III-Investigacion en Salud (PI21/01019)
Prostate Cancer Foundation (18YOUN19)
- License Information
-
More Information
Article History
Received: 2 March 2023
Revised: 6 July 2023
Accepted: 10 July 2023
First Online: 2 August 2023
Competing interests
: JH has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Eisai, Ipsen, Novartis, AAA, Angelini, Roche, Pfizer, LEO Pharma. EG has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific. EG has received research grants from Pfizer, AstraZeneca, Astellas, and Lexicon Pharmaceuticals. RPL receives grant support from AstraZeneca and Roche Pharma and has received honoraria for speaker engagements or advisory roles from Astellas and Roche Pharma.
: The Institutional Review Board approved this retrospective study. Informed consent for computational image analysis was waived. All patients included in the clinical trial Lenvatinib Efficacy in Metastatic Neuroendocrine Tumours (TALENT) NCT02678780 provided written informed consent.
